GlassScriptPhysician profile
Fayyaz Mahmood
NPI 1396709523
$1,098.34
in general payments reported to CMS, 2019-2025
23 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $19.42 · 2021: $116 · 2022: $397 · 2023: $233 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.86 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $223.14 | 2019-2025 | Tysabri |
| Teva Pharmaceuticals USA, INC. | $118.82 | 2021-2022 | |
| Celgene Corporation | $73.60 | 2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $67.74 | 2019-2023 | |
| Acorda Therapeutics, INC | $63.90 | 2019-2022 | |
| Lundbeck LLC | $60.47 | 2023 | Vyepti |
| Pfizer INC. | $55.09 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $47.04 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.90 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $45.17 | 2019-2022 | |
| Emd Serono, INC. | $43.81 | 2022 | |
| Ucb, INC. | $35.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.87 | 2021 | |
| Genzyme Corporation | $26.67 | 2022 | |
| Sk Life Science, INC. | $20.71 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $20.36 | 2023 | Valtoco |
| Jazz Pharmaceuticals INC. | $19.84 | 2022 | |
| Neurocrine Biosciences, INC. | $19.66 | 2023 | Ongentys, Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Tg Therapeutics, INC. | $17.46 | 2023 | |
| Genentech USA, INC. | $17.08 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.87 | 2021 | |
| Acadia Pharmaceuticals INC | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fayyaz Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.